FDA Orange Book · active-ingredient family
Cangrelor
Cangrelor is approved as 1 brand and 2 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:KENGREAL · NDA 204958
1
Brand (NDA)
2
Generics (ANDA)
7
Listed patents
0
Exclusivity periods
Brand (NDA) products · powder
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| KENGREALRLD | CHIESI | NDA 204958 | AP | Jun 22, 2015 |
Generic (ANDA) products (2)
Listed patents (7)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9925265 | May 13, 2029 | in 2 yr 11 mo | U-2260 |
| 9427448 | Nov 10, 2030 | in 4 yr 6 mo | U-1926 |
| 8680052 | Mar 09, 2033 | in 6 yr 10 mo | U-2979 |
| 10039780 | Jul 10, 2035 | in 9 yr 2 mo | U-2260 |
| 9439921 | Jul 10, 2035 | in 9 yr 2 mo | Product |
| 9700575 | Jul 10, 2035 | in 9 yr 2 mo | Product |
| 9295687 | Jul 10, 2035 | in 9 yr 2 mo | Product |
Cangrelor — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
